Pamorelin LA 22.5mg (Triptorelin Powder Vials) 22.5MG

Pamorelin LA 22.5mg is a prescription medication containing triptorelin, a synthetic peptide used in hormone therapy. This injectable powder formulation is designed for extended-release treatment. It is commonly used in conditions requiring androgen deprivation. Suitable for adults under medical supervision.

Strength

22.5MG

Manufacturer / TM Owner

DEBIOPHARM RESEARCH

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Pamorelin LA 22.5mg is primarily used in hormone therapy to manage conditions like advanced prostate cancer and endometriosis by reducing hormone levels. It may also be prescribed for precocious puberty or uterine fibroids. The 22.5mg strength provides extended-release benefits, reducing dosing frequency. Always used as directed by a healthcare provider.

Side Effects

Pamorelin LA 22.5mg works by temporarily suppressing certain hormones, which can lead to changes in bodily functions. Users may experience effects such as hot flashes or mood changes during treatment. These effects vary and are typically monitored by a healthcare professional.

Precautions & Warnings

Store Pamorelin LA 22.5mg powder at controlled room temperature, away from moisture and light. Keep out of reach of children and pets. Do not use if the vial is damaged or the powder appears discolored. Always follow healthcare provider instructions for preparation and administration.

Avoid Interactions

Pamorelin LA 22.5mg may interact with other hormone therapies or medications affecting hormone levels. Caution is advised when combining with drugs that alter electrolyte balance or cardiovascular function. Alcohol and certain supplements may also interact; consult a healthcare provider before use.

References

Frequently Asked Questions

Pamorelin LA 22.5mg is used in hormone therapy for conditions like advanced prostate cancer, endometriosis, or precocious puberty.

It is an injectable powder that must be prepared and administered by a healthcare professional as directed.

Common effects may include hot flashes, mood changes, or injection site reactions; report persistent issues to a doctor.

Pamorelin LA 22.5mg requires a prescription and should only be purchased from licensed pharmacies.

Pamorelin LA 22.5mg is a prescription medication and is not classified as a controlled substance.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.